Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia
Status:
Recruiting
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
Study is a phase I study to determine the maximum tolerated dose of adding Loncastuximab
Tesirine to Aclabrutinib in the treatment of chronic lymphocytic leukemia.